Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 4
1(20.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(3)
Phase 4(1)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03948191Phase 4Completed

99Tc-MDP for Thyroid-Associated Ophthalmopathy

Role: lead

NCT03429634Early Phase 1Completed

Balloon-Stent Kissing Technique Versus Jailed Wire Technique for the Coronary Bifurcation Lesions

Role: lead

NCT03333499Phase 1Unknown

the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure

Role: lead

NCT03235167Phase 1Unknown

Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy

Role: lead

NCT03282435Phase 1Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Role: lead

All 5 trials loaded